|Bid||55.84 x 100|
|Ask||0.00 x 0|
|Day's Range||98.94 - 99.25|
|52 Week Range||84.58 - 100.00|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.06%|
ETF adoption has rapidly accelerated in recent years, with many investors steering to cheap ETFs to potentially bolster long-term investment returns. There are 2,040 U.S.-listed ETFs on the market with ...
Goldman Sachs Asset Management is ramping up a price war with the pending launch of a new "smart-beta" exchange-traded fund with an expense ratio as low as 0.09% (or 9 basis points) -- a level even lower than some passive index funds, says Moody's Investors Service. Analyst Stephen Tu writes: GSAM’s move expands the ETF price war beyond plain vanilla ETFs into smart-beta ETFs, implying that the industry’s higher pricing assumptions for smart-beta products will not hold.
Zimmer Biomet registered net sales of $1.95 billion, exceeding the analysts’ estimate, and saw year-over-year sales growth of around 1.1%.